ABUS Nasdaq Pharmaceutical Preparations Financials FY2016βFY2025
Arbutus Biopharma Corp had $14.1M of revenue in fiscal 2025, up 128.2% on the year before. Over five years, revenue changed +15.3% a year on average.
Last close Β· Oct 23, 2026
$4.20
0.2%Hi! I read Arbutus Biopharma Corpβs latest annual report (fiscal 2025). Here is what stands out:
Good So-so Weak
Are sales growing?
+128.2%
Yes. Sales grew 128.2% last year.
Does it make a profit?
β237.9%
No. It lost money last year.
Does profit turn into cash?
β281.5%
No. It spent more cash than it brought in.
How healthy are the accounts?
3 / 8
Weak. It passes 3 of 8 health tests.
How is the share priced?
5.3x
One share costs 5.3 times its yearly profit per share.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
KIRA Β· Arbutus Biopharma Corp had $14.1M of revenue in fiscal 2025, up 128.2% on the year before. Over five years, revenue changed +15.3% a year on average. Its operating margin was β271.0%, up 965.8Β pts: of every 100 in sales, about β271 is left after running the business.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
Revenue
Margins, % of revenue
Margins, % of revenue
KIRA Β· Arbutus Biopharma Corp lost $33.5M in fiscal 2025.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
Net income
Diluted EPS
Diluted EPS
How much cash comes in, and where does it go?
KIRA Β· Free cash flow was β$39.6M in fiscal 2025, β281.5% of revenue.
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations vs capital spending
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
Diluted shares outstanding (annual)
KIRA Β· No open-market insider trades in the last 12 months.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Can it carry its debts, and how well does it use its money?
KIRA Β· Arbutus Biopharma Corp has $91.5M more cash than debt.
Cash, debt and the ratios that show how comfortably Arbutus Biopharma Corp can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $155M | $147M | $126M | $123M | $91.5M |
| Debt incl. finance leases | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Debt / equity | 0.0x | 0.0x | 0.0x | 0.0x | 0.0x |
| Interest coverage | β25.7x | β37.9x | β170.2x | β557.1x | β393.4x |
| Current ratio | 14.3x | 4.6x | 5.9x | 8.2x | 15.7x |
| Quick ratio | 14.3x | 4.6x | 5.9x | 8.2x | 15.7x |
| Total assets | $204M | $195M | $144M | $132M | $94.6M |
| Total liabilities | $35.0M | $58.6M | $38.4M | $34.3M | $18.0M |
| Shareholders' equity | $169M | $137M | $106M | $97.4M | $76.6M |
| Net debt (β = net cash) | β$155M | β$147M | β$126M | β$123M | β$91.5M |
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
KIRA Β· Arbutus Biopharma Corp passes 3 of 8 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β | β | β |
| F-score | β / 3 | 3 / 7 | 2 / 7 | 3 / 7 | 3 / 7 | 4 / 7 | 3 / 8 | 1 / 8 | 2 / 8 | 3 / 8 |
| Accruals ratio | β118.3% | β13.9% | 4.6% | β49.6% | β10.1% | β5.1% | β17.1% | 7.7% | β3.7% | 5.4% |
| Altman Z'' | β13.86 | β6.61 | β3.17 | β31.45 | β19.00 | β10.63 | β15.91 | β24.58 | β28.68 | β39.67 |
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $1.5M | $10.7M | $5.9M | $6.0M | $6.9M | $11.0M | $39.0M | $18.1M | $6.2M | $14.1M |
| Research and development | $61.3M | $62.7M | $57.9M | $57.6M | $49.3M | $65.5M | $84.4M | $73.7M | $54.0M | $25.2M |
| Operating income | β$492M | β$111M | β$89.8M | β$144M | β$57.8M | β$73.5M | β$65.5M | β$78.1M | β$76.3M | β$38.2M |
| Interest expense | $0.0M | $0.3M | $0.2M | $2.1M | $4.0M | $2.9M | $1.7M | $0.5M | $0.1M | $0.1M |
| Pretax income | β$489M | β$109M | β$61.3M | β$166M | β$63.7M | β$7.7M | β$28.7M | β$14.8M | β$1.7M | $12.0M |
| Income tax | β$105M | β$24.3M | β$4.3M | β$12.7M | $0.0M | $0.0M | $4.4M | $0.0M | $0.0M | $0.0M |
| Net income | β$384M | β$84.4M | β$57.1M | β$154M | β$63.7M | β$76.2M | β$69.5M | β$72.8M | β$69.9M | β$33.5M |
| Net income to common | β$384M | β$85.3M | β$67.2M | β$165M | β$75.9M | β$88.4M | β$69.5M | β | β | β |
| Diluted EPS | β$7.24 | β$1.56 | β$1.21 | β$2.89 | β$1.00 | β$0.83 | β$0.46 | β$0.44 | β$0.38 | β$0.17 |
| Diluted shares | 0.05B | 0.05B | 0.06B | 0.06B | 0.08B | 0.11B | 0.15B | 0.17B | 0.19B | 0.19B |
| Cash flow | ||||||||||
| Cash from operations | β$57.9M | β$48.6M | β$67.9M | β$71.0M | β$51.4M | β$67.5M | β$35.4M | β$85.9M | β$64.9M | β$39.6M |
| Capital expenditure | $4.0M | $7.3M | $1.1M | $0.6M | $0.2M | $0.8M | $0.5M | $1.0M | $0.2M | $0.0M |
| Free cash flow | β$61.9M | β$55.9M | β$69.0M | β$71.6M | β$51.7M | β$68.3M | β$35.9M | β$86.9M | β$65.0M | β$39.6M |
| Depreciation and amortization | $1.1M | $2.0M | $2.2M | $2.0M | $2.0M | $1.8M | $1.4M | $1.4M | $1.4M | $0.4M |
| Stock-based compensation | $39.2M | $15.1M | $6.2M | $6.8M | $6.2M | $6.4M | $7.2M | $9.3M | $9.0M | $7.0M |
| Balance sheet | ||||||||||
| Cash and short-term investments | $131M | $126M | $125M | $90.8M | $123M | $155M | $147M | $126M | $123M | $91.5M |
| Total debt | β | β | β | β | β | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Current assets | $133M | $129M | $129M | $93.8M | $128M | $161M | $151M | $132M | $127M | $94.5M |
| Current liabilities | $10.6M | $14.6M | $11.2M | $7.8M | $9.5M | $11.2M | $32.9M | $22.5M | $15.6M | $6.0M |
| Property and equipment, net | $6.9M | $12.2M | $10.1M | $8.7M | $6.9M | $6.0M | $5.1M | $4.7M | $3.3M | $0.0M |
| Goodwill | $24.4M | $24.4M | $22.5M | $0.0M | β | β | β | β | β | β |
| Intangible assets | $99.4M | $58.6M | $43.8M | $0.0M | β | β | β | β | β | β |
| Total assets | $276M | $237M | $228M | $106M | $137M | $204M | $195M | $144M | $132M | $94.6M |
| Total liabilities | $72.9M | $54.7M | $27.7M | $32.8M | $35.1M | $35.0M | $58.6M | $38.4M | $34.3M | $18.0M |
| Preferred stock | β | $48.9M | β | β | β | β | β | β | β | β |
| Shareholders' equity | $203M | $182M | $200M | $72.7M | $102M | $169M | $137M | $106M | $97.4M | $76.6M |
| Margins | ||||||||||
| Operating margin | β32,973.8% | β1,036.7% | β1,510.2% | β2,394.0% | β836.1% | β669.1% | β167.8% | β430.5% | β1,236.7% | β271.0% |
| EBITDA margin | β32,900.5% | β1,017.8% | β1,473.5% | β2,360.2% | β807.5% | β653.2% | β164.1% | β422.8% | β1,214.4% | β268.4% |
| Net margin | β25,765.5% | β788.9% | β959.8% | β2,557.4% | β922.0% | β693.9% | β178.0% | β401.6% | β1,133.0% | β237.9% |
| FCF margin | β4,150.3% | β522.5% | β1,160.7% | β1,191.1% | β747.3% | β622.0% | β91.9% | β479.3% | β1,053.8% | β281.5% |
| Returns | ||||||||||
| Return on capital | β | β | β | β | β | β411.3% | β | β | β | β |
| Return on capital employed | β185.3% | β49.8% | β41.4% | β147.3% | β45.3% | β38.0% | β40.3% | β64.1% | β65.7% | β43.1% |
| Return on equity | β189.2% | β43.8% | β29.8% | β112.6% | β73.0% | β56.2% | β45.4% | β60.0% | β68.8% | β38.5% |
| Return on assets | β139.2% | β32.9% | β24.5% | β92.2% | β52.5% | β44.6% | β34.7% | β42.9% | β50.6% | β29.6% |
| Return on tangible equity | β485.1% | β85.8% | β50.1% | β226.6% | β74.4% | β52.2% | β50.8% | β68.7% | β71.8% | β43.7% |
| Growth | ||||||||||
| Revenue growth | β | 617.6% | β44.4% | 1.1% | 15.0% | 58.9% | 255.1% | β53.5% | β66.0% | 128.2% |
| Share count change | β | 3.1% | 1.1% | 3.2% | 32.8% | 40.1% | 42.1% | 10.0% | 11.8% | 3.2% |
| Financial health | ||||||||||
| Debt / equity | β | β | β | β | β | 0.0x | 0.0x | 0.0x | 0.0x | 0.0x |
| Interest coverage | β | β425.0x | β397.3x | β68.3x | β14.4x | β25.7x | β37.9x | β170.2x | β557.1x | β393.4x |
| Current ratio | 12.5x | 8.8x | 11.5x | 12.0x | 13.4x | 14.3x | 4.6x | 5.9x | 8.2x | 15.7x |
| Quick ratio | 12.5x | 8.8x | 11.5x | 12.0x | 13.4x | 14.3x | 4.6x | 5.9x | 8.2x | 15.7x |
| Capital allocation | ||||||||||
| Capex / revenue | 268.0% | 67.9% | 19.1% | 9.8% | 3.3% | 7.4% | 1.3% | 5.6% | 2.9% | 0.0% |
| Stock comp / revenue | 2,626.4% | 141.3% | 105.0% | 113.1% | 89.1% | 58.5% | 18.4% | 51.3% | 145.6% | 49.4% |
| Quality scores | ||||||||||
| Piotroski F-score | β | 3.0 | 2.0 | 3.0 | 3.0 | 4.0 | 3.0 | 1.0 | 2.0 | 3.0 |
| Altman Z'' | β13.9 | β6.6 | β3.2 | β31.5 | β19.0 | β10.6 | β15.9 | β24.6 | β28.7 | β39.7 |
| Accruals ratio | β118.3% | β13.9% | 4.6% | β49.6% | β10.1% | β5.1% | β17.1% | 7.7% | β3.7% | 5.4% |
Source: SEC EDGAR XBRL filings (CIK 0001447028). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.
